GF Fund Management CO. LTD. Takes Position in Pfizer Inc. (NYSE:PFE)

GF Fund Management CO. LTD. acquired a new stake in Pfizer Inc. (NYSE:PFE) in the 4th quarter, HoldingsChannel.com reports. The fund acquired 139,762 shares of the biopharmaceutical company’s stock, valued at approximately $3,708,000.

Several other large investors have also bought and sold shares of the company. Rialto Wealth Management LLC acquired a new position in shares of Pfizer in the 4th quarter worth approximately $26,000. Clarity Asset Management Inc. bought a new stake in Pfizer during the fourth quarter worth approximately $27,000. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer in the fourth quarter worth approximately $28,000. Noble Wealth Management PBC bought a new position in shares of Pfizer in the fourth quarter valued at $31,000. Finally, Bernard Wealth Management Corp. acquired a new stake in shares of Pfizer during the 4th quarter valued at $33,000. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on PFE shares. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Cantor Fitzgerald initiated coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target on the stock. Citigroup restated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. UBS Group raised their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Stock Performance

PFE stock opened at $23.33 on Friday. The stock has a market cap of $132.66 billion, a P/E ratio of 16.55, a P/E/G ratio of 0.64 and a beta of 0.58. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a 50 day simple moving average of $23.38 and a 200 day simple moving average of $25.17. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter last year, the business posted $0.82 EPS. The company’s revenue for the quarter was down 7.8% on a year-over-year basis. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.37%. Pfizer’s dividend payout ratio is 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.